UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $6.00 | Buy | Craig Hallum |
| 10/7/2024 | $4.00 | Neutral | UBS |
| 2/25/2022 | $3.00 → $2.50 | Market Perform | SVB Leerink |
| 2/2/2022 | $7.00 → $3.00 | Underperform → Market Perform | Cowen & Co. |
| 2/2/2022 | $6.00 | Buy | Canaccord Genuity |
| 1/19/2022 | $3.00 | Market Perform | SVB Leerink |
| 1/10/2022 | $9.00 → $3.50 | Neutral | Citigroup |
| 1/7/2022 | $9.00 → $3.50 | Neutral → Underperform | Credit Suisse |
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health, positioning Clover as a national leader in AI-enabled healthcare transformation. In his testimony, Andrew highlighted how Clover's proprietary AI platform empowers physicians to deliver more personalized, timely care at the point of service, particularly to seniors in rural and other underserved communities. Motivated by a personal mission to improve care delivery following the lo
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an i
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage
Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00
UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten
WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a
WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. Annual reconstitution of the Russell indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, also results in automatic membership in the large-cap Russell 1000® Index or small-cap Russell 2000® Index along with the relevant growth and value style indexes. FTSE Russe
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage
WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Second Quarter 2025 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2025 Earnings Conference CallWhen: Tuesday, August 5, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-245-3047 (for U.S. caller
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso